Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim and Cryoablation In-Situ Vaccine for Metastatic Cancer
NCT00861107Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Aug 2009
- Primary completion
- Mar 2011
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of allostim in metastatic cancer, sponsored by Mirror Biologics, Inc.. Started Aug 2009; status: completed.
02
Drugs
allostim
03
Conditions
metastatic cancer
Beyond the preview
Go deeper on NCT00861107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00861107.